12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ublituximab: Phase I/II started

In July, TG Therapeutics began an open-label, U.S. Phase I/II trial to evaluate ublituximab in patients with B-cell NHL relapsed or refractory to rituximab. The Phase I portion is evaluating 450, 600, 900 and 1,200 mg IV ublituximab administered on days 1, 8, 15 and 22 of each cycle...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >